Real‐world evidence following a mandatory treatment break after a 1‐year prophylactic treatment with calcitonin gene‐related peptide (pathway) monoclonal antibodies

BACKGROUND: Current German and European guidelines suggest migraine patients undertake a treatment break after 9 to 12 months of treatment with CGRP (pathway) monoclonal antibodies. METHODS: Clinical routine data of highly resistant migraine patients were analyzed before treatment with CGRP monoclon...

Descripción completa

Detalles Bibliográficos
Autores principales: Nsaka, Michael, Scheffler, Armin, Wurthmann, Sebastian, Schenk, Hannah, Kleinschnitz, Christoph, Glas, Martin, Holle, Dagny
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9304830/
https://www.ncbi.nlm.nih.gov/pubmed/35687795
http://dx.doi.org/10.1002/brb3.2662

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9304830/
https://www.ncbi.nlm.nih.gov/pubmed/35687795
http://dx.doi.org/10.1002/brb3.2662

Ejemplares similares